MarketPulse

NASH

4 articles
BenzingaBenzinga··Prnewswire

Viking Therapeutics to Report Q1 2026 Results; Obesity Drug VK2735 in Focus

Viking Therapeutics will report Q1 2026 earnings April 29 after market close, showcasing progress on obesity and metabolic disorder treatments.
VKTXfinancial resultsPhase 3 trials
BenzingaBenzinga··Prnewswire

Viking Therapeutics Expands Investor Outreach With Spring Conference Circuit

Viking Therapeutics to present at two major biotech conferences in April 2026, conducting investor meetings in New York and Boston.
VKTXinvestor conferencesclinical trials
BenzingaBenzinga··Prnewswire

Galmed Files 2025 Annual Report as Aramchol Advances Through Clinical Pipeline

Galmed files 2025 annual report detailing Aramchol development for NASH and cardiometabolic diseases, including clinical trial progress and regulatory disclosures.
GLMDFDA approvalclinical trials
The Motley FoolThe Motley Fool··Eric Trie

ORBIMED Advisors Reduces Terns Pharma Position Despite 858% Annual Gain

ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.
LLYTERNEWvaluationbiotech